Cargando…

Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model

Although bevacizumab maintenance following bevacizumab in combination with chemotherapy has demonstrated significant prolongation of progression-free survival in clinical studies in patients with ovarian cancer, the majority of the cancer cases in the study were of the serous histotype; therefore, d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishikura, Nobuyuki, Yorozu, Keigo, Kurasawa, Mitsue, Yanagisawa, Mieko, Sugimoto, Masamichi, Yamamoto, Kaname
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667843/ https://www.ncbi.nlm.nih.gov/pubmed/31322247 http://dx.doi.org/10.3892/or.2019.7211

Ejemplares similares

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
por: Iwai, Toshiki, et al.
Publicado: (2016)

Biomarkers for antitumor activity of bevacizumab in gastric cancer models
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2012)

Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
por: Masuda, Chinami, et al.
Publicado: (2019)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors
por: Ishikura, Nobuyuki, et al.
Publicado: (2022)

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies
por: Iwai, Toshiki, et al.
Publicado: (2018)

Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy
por: Iwai, Toshiki, et al.
Publicado: (2021)

PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8(+) T cells in hematogenous metastasis model with lymphocyte infusion
por: Masuda, Chinami, et al.
Publicado: (2021)

Methods for preparing tissue microarray slides using xenografts with different levels of HER2 expression to standardize HER2 detection
por: Yorozu, Keigo, et al.
Publicado: (2022)

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
por: Iwai, Toshiki, et al.
Publicado: (2021)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
por: Mayenga, Marie, et al.
Publicado: (2023)

MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells
por: Nishidate, Masanobu, et al.
Publicado: (2017)

Continued Exploration of Bevacizumab in Breast Cancer
por: Mehta, Rita S., et al.
Publicado: (2009)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy
por: Rebelo de Almeida, Cátia, et al.
Publicado: (2020)

Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
por: Bukowski, Ronald M
Publicado: (2010)

Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
por: Paudyal, Bishnuhari, et al.
Publicado: (2014)

ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
por: Kikuchi, Miyu, et al.
Publicado: (2021)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma
por: MICHISHITA, Masaki, et al.
Publicado: (2015)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
por: Taniguchi, Hiroya, et al.
Publicado: (2018)

Necrotizing Fasciitis in a Patient with Metastatic Clear Cell Ovarian Carcinoma Treated with Bevacizumab
por: Haider, Asim, et al.
Publicado: (2022)

T2(∗) Relaxation Time Obtained from Magnetic Resonance Imaging of the Liver Is a Useful Parameter for Use in the Construction of a Murine Model of Iron Overload
por: Matsuo-Tezuka, Yukari, et al.
Publicado: (2019)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

Visualization of (57)Fe-Labeled Heme Isotopic Fine Structure and Localization of Regions of Erythroblast Maturation in Mouse Spleen by MALDI FTICR-MS Imaging
por: Kihara, Makoto, et al.
Publicado: (2017)

Bevacizumab helped resolve pericardial and pleural effusion that was associated with malignant ovarian clear cell carcinoma
por: Ueda, Tomoko, et al.
Publicado: (2016)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
por: Aravantinos, Gerasimos, et al.
Publicado: (2014)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
por: Yoshimoto, Toshiaki, et al.
Publicado: (2020)

Effective Inhibition of Xenografts of Hepatocellular Carcinoma (HepG2) by Rapamycin and Bevacizumab in an Intrahepatic Model
por: Ong, Lai-Chun, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_muov9k41op6ct901r4gd8fs496